{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:09:42Z","timestamp":1788790182847,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40261-020-00941-3","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T08:03:51Z","timestamp":1593763431000},"page":"847-859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-2695","authenticated-orcid":false,"given":"Tomohiko","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,3]]},"reference":[{"key":"941_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucl Nucl Nucleic Acids. 2011;30:1018\u201329.","journal-title":"Nucl Nucl Nucleic Acids."},{"key":"941_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764.","journal-title":"Nat Commun."},{"key":"941_CR3","doi-asserted-by":"publisher","first-page":"31003","DOI":"10.1038\/srep31003","volume":"6","author":"H Matsuo","year":"2016","unstructured":"Matsuo H, Tsunoda T, Ooyama K, Sakiyama M, Sogo T, Takada T, et al. Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2. Sci Rep. 2016;6:31003.","journal-title":"Sci Rep"},{"key":"941_CR4","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1038\/srep05227","volume":"4","author":"A Nakayama","year":"2014","unstructured":"Nakayama A, Matsuo H, Nakaoka H, Nakamura T, Nakashima H, Takada Y, et al. Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. Sci Rep. 2014;4:5227.","journal-title":"Sci Rep."},{"key":"941_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald J, Khanna P, Bae S, Singh M, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431\u201346.","journal-title":"Arthritis Care Res."},{"key":"941_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"941_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","volume":"73","author":"F Sivera","year":"2014","unstructured":"Sivera F, Andr\u00e9s M, Carmona L, Kydd A, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73:328\u201335.","journal-title":"Ann Rheum Dis"},{"key":"941_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1759720X16646703","volume":"8","author":"SE Sattui","year":"2016","unstructured":"Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016;8:145\u201359.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"941_CR9","doi-asserted-by":"publisher","first-page":"7931","DOI":"10.1073\/pnas.0400973101","volume":"101","author":"K Okamoto","year":"2004","unstructured":"Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci USA. 2004;101:7931\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"941_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1124\/jpet.110.174540","volume":"336","author":"K Matsumoto","year":"2011","unstructured":"Matsumoto K, Okamoto K, Ashizawa N, Nishino T. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011;336:95\u2013103.","journal-title":"J Pharmacol Exp Ther"},{"key":"941_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/jcpt.12392","volume":"41","author":"T Hosoya","year":"2016","unstructured":"Hosoya T, Sasaki T, Hashimoto H, Sakamoto R, Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2016;41:298\u2013305.","journal-title":"J Clin Pharm Ther"},{"key":"941_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10067-016-3474-8","volume":"36","author":"T Hosoya","year":"2017","unstructured":"Hosoya T, Sasaki T, Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clin Rheumatol. 2017;36:649\u201356.","journal-title":"Clin Rheumatol"},{"key":"941_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/jcpt.12391","volume":"41","author":"T Hosoya","year":"2016","unstructured":"Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. J Clin Pharm Ther. 2016;41:290\u20137.","journal-title":"J Clin Pharm Ther"},{"key":"941_CR14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10157-014-0935-8","volume":"18","author":"T Hosoya","year":"2014","unstructured":"Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18:876\u201384.","journal-title":"Clin Exp Nephrol"},{"key":"941_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40261-018-0699-0","volume":"38","author":"T Hosoya","year":"2018","unstructured":"Hosoya T, Ishikawa T, Ogawa Y, Sakamoto R, Ohashi T. Multicenter, open-label study of long-term topiroxostat (FYX-051) administration in Japanese hyperuricemic patients with or without gout. Clin Drug Investig. 2018;38:1135\u201343.","journal-title":"Clin Drug Investig."},{"key":"941_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/nep.13177","volume":"23","author":"T Mizukoshi","year":"2018","unstructured":"Mizukoshi T, Kato S, Ando M, Sobajima H, Ohashi N, Naruse T, et al. Renoprotective effects of topiroxostat for hyperuremic patients with overt diabetic nephropathy study (ETUDE Study): a prospective, randomized, multicenter clinical trial. Nephrology. 2018;23:1023\u201330.","journal-title":"Nephrology."},{"key":"941_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s10157-018-1530-1","volume":"22","author":"T Wada","year":"2018","unstructured":"Wada T, Hosoya T, Honda D, Sakamoto R, Narita K, Sasaki T, et al. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Clin Exp Nephrol. 2018;22:860\u201370.","journal-title":"Clin Exp Nephrol"},{"key":"941_CR18","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1080\/14397595.2018.1519149","volume":"29","author":"M Hakoda","year":"2019","unstructured":"Hakoda M, Kasagi F. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan. Mod Rheumatol. 2019;29:880\u20134.","journal-title":"Mod Rheumatol"},{"key":"941_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13075-019-1860-8","volume":"21","author":"B Stiburkova","year":"2019","unstructured":"Stiburkova B, Pavelcova K, Pavlikova M, Je\u0161ina P, Pavelka K. The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. Arthritis Res Ther. 2019;21:77.","journal-title":"Arthritis Res Ther."},{"key":"941_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/tpj.2015.101","volume":"17","author":"RL Roberts","year":"2016","unstructured":"Roberts RL, Wallace MC, Phipps-Green AJ, Topless R, Drake JM, Tan P, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenom J. 2016;17:201\u20133.","journal-title":"Pharmacogenom J"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00941-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00941-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00941-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:46:16Z","timestamp":1625273176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00941-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00941-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"3 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"YK is a medical advisor of Fuji Yakuhin Co., Ltd., and received consultant fees. TI, TH and YS are employees of Fuji Yakuhin Co., Ltd., TM, TN and KI are employees of Sanwa Kagaku Kenkyusho Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was carried out in accordance with the good post-marketing study practice standards specified by the Ministry of Health, Labor and Welfare in Japan. According to good post-marketing study practice in Japan, ethics approval was not required for this post-marketing study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"According to good post-marketing study practice in Japan, informed consent was not required for this post-marketing study. As such, informed consent was not obtained from the individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}